Guiling Li

机构：Union Hospital, Beijing Institute of Neurosurgery, Wuhan Union Hospital, Puer University, Beijing Tsinghua Chang Gung Hospital, Huazhong University of Science and Technology · ORCID：0000-0002-3220-7554

发表论文 59 篇 · 总被引 1178 次 · h-index 16

代表论文

• Safety and antitumour activity of cadonilimab, an anti-PD-1/CTLA-4 bispecific antibody, for patients with advanced solid tumours (COMPASSION-03): a multicentre, open-label, phase 1b/2 trial (2023 · The Lancet Oncology · 被引 207)
• Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China (2024 · The Lancet · 被引 112)
• Anti-LAG-3 antibody LBL-007 plus anti-PD-1 antibody toripalimab in advanced nasopharyngeal carcinoma and other solid tumors: an open-label, multicenter, phase Ib/II trial (2025 · Journal of Hematology & Oncology · 被引 27)
• Efficacy and safety of serplulimab plus nab-paclitaxel in previously treated patients with PD-L1–positive advanced cervical cancer: a phase II, single-arm study (2023 · Frontiers in Immunology · 被引 15)
• Clinical Efficacy and Safety of Immunotherapy Retreatment in Metastatic Cervical Cancer: A Retrospective Study (2023 · OncoTargets and Therapy · 被引 15)
• Combining cisplatin with Pinellia pedatisecta Schott lipid-soluble extract induces tumor immunogenic cell death in cervical cancer (2024 · Phytomedicine · 被引 12)